Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03697512
Other study ID # IELSG47
Secondary ID 2018-002364-44
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date September 27, 2019
Est. completion date June 15, 2027

Study information

Verified date May 2023
Source International Extranodal Lymphoma Study Group (IELSG)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Single-arm, phase II clinical trial of patients with Extranodal Marginal Zone Lymphoma (EMZL). It is planned to recruit 130 patients. Additional patients with Splenic Marginal Zone Lymphoma (SMZL), up to 30, and Nodal Marginal Zone Lymphoma (NMZL), up to 15, will be included in the trial in order to preliminary explore the clinical activity and safety of the combination treatment proposed. The study primary endpoints will be analysed on the EMZL population. Outcome of patients with SMZL and NMZL will be analysed and reported separately


Description:

Marginal zone lymphomas (MZL) represent a group of indolent B-cell lymphomas that arises from marginal zone B-cells in extranodal tissues, such as spleen and mucosa associated lymphoid tissues, and more rarely also in nodal tissues. MZL comprises 5 to 17% of all non-Hodgkin lymphomas (NHL) in adults. The 2016 World Health Organization (WHO) recognized three separate subtypes of MZL according to their primary localization, namely the: 1. extranodal MZL (EMZL) of mucosa-associated lymphoid tissue (MALT), also known as MALT lymphoma 2. splenic MZL (SMZL) 3. nodal MZL (NMZL). These three subtypes are distinct disease entities that are classified together because they all seem to originate from post germinal centre marginal zone B-cells. MALIBU trial is a prospective multicenter trial combining rituximab and ibrutinib in front-line for patients with MZL, including EMZL, SMZL and NMZL Aim of the study is to assess the safety and efficacy of the combination of rituximab and ibrutinib in EMZL patients and to explore its activity in SMZL and NMZL as exploratory subset.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 175
Est. completion date June 15, 2027
Est. primary completion date June 15, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Chemotherapy and immunotherapy-naïve, symptomatic and in need of treatment patients, with histologically proven CD20-positive MZL, not eligible for local therapy, including: 1. EMZL (MALT Lymphoma) patients with MALT- IPI score 1-2 in need of systemic therapy. Either de novo or relapsed following local therapy (including surgery, radiotherapy and antibiotics for H. pylori-positive gastric lymphoma) arisen at any extranodal site with MALT-international prognostic index (IPI) score 1-2 at the time of study entry. 1.1.The following patients with gastric MALT Lymphoma can be entered: 1. H. pylori-negative cases, either de novo (non pretreated) or at relapse following local therapy (i.e., surgery, radiotherapy or antibiotics). 2. H. pylori-positive cases at diagnosis, who either first line antibiotics or further local treatment (surgery or radiotherapy), including patients with: - clinical (endoscopic) and histological evidence of disease progression at any time post H. pylori eradication; - clinical (endoscopic) and histological relapse (without H. pylori re-infection), after a remission patients; - persistent (stable) lymphoma at = 1 year post H. pylori eradication. 1.2. Similar consideration may be applied to patients with ocular adnexal lymphoma treated with antibiotics. 2. SMZL patients in need of therapy. Either de novo or relapsed following local therapy [including surgery and antiviral therapy for Hepatitis C virus (HCV)]. Patient must have a symptomatic disease requiring treatment and be not eligible for splenectomy or not willing to undergo splenectomy. 2.1. Patients with SMZL can be entered if any of the following criteria is present: 1. bulky progressive or painful splenomegaly; 2. enlarged lymph nodes or involvement of extranodal sites with or without cytopenias , i.e. involvement of =3 nodal sites, each with a diameter of =3 cm. Any nodal tumor mass with a diameter of =7 cm (GELG criteria, as adopted in follicular lymphoma); 3. one of the following symptomatic/progressive cytopenias: - Hgb < 10 g/dL; - ANC < 1000/µL: - PLT< 80 000/µL whatever the reason (autoimmune or hypersplenism or bone marrow infiltration). 2.2. Splenectomised patients with rapidly raising lymphocyte counts, lymphadenopathy or involvement of extranodal sites can be entered. 2.3. SMZL with concomitant HCV infection who have not responded to or are relapsed after antiviral therapy can be entered. 3. NMZL patients in need of therapy Either, de novo presenting with disseminated disease or relapsed after local radiotherapy or following antiviral therapy for HCV. Localized nodal MZL is not eligible. - Measurable or evaluable disease. - Ann Arbor II-IV. Stage I disease may be eligible only if not candidate to local therapy (surgery or radiotherapy). - Age = 18. - Life expectancy of at least 1 year. - ECOG Performance status 0-2. - Adequate bone marrow, kidney and liver function - For women of childbearing potential only: negative serum pregnancy test done within 7 days prior to study drugs administration or within 14 days if with a confirmatory urine pregnancy test within 7 days prior to the first study drugs administration. - Fertile male or female patients of childbearing potential and their partners must use higly effective contraception methods during the study and for at least 12 months after the last dose of subcutaneous rituximab. In case hormonal methods of birth control is used a barrier method must be added. - Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: 1. Any type of lymphoma other than MZL (including MZL with histologic transformation to high-grade lymphoma). 2. Localized (stage IE and IIE) MALT lymphoma, for example gastric, ocular and cutaneous lymphoma, that may benefit from local therapy only (surgery or radiotherapy). 3. Known CNS involvement of MZL. 4. Any previous systemic treatment with immunotherapy or chemotherapy or with BTK inhibitors. 5. Major surgery within 4 weeks prior to registration. 6. History of stroke or intracranial bleeding within 6 months. 7. Known bleeding diathesis (eg, von Willebrand's disease) or hemophilia. 8. Concurrent use of warfarin of other vitamin K antagonists. 9. Concurrent use of strong cytochrome P450 (CYP)3A4/5 inhibitors (see http://medicine.iupui.edu/clinpharm/ddis/clinical-table/). 10. Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk. 11. International normalized ratio (INR) or prothrombin time (PT) =1.5 ULN. Partial thromboplastin time (PTT) or activated PTT (aPTT) =1.5 ULN unless due to lupus anticoagulant. 12. Vaccinated with live, attenuated vaccines within 4 weeks prior to randomization. 13. Clinically significant hypersensitivity (e.g., anaphylactic or anaphylactoid reactions to the compound of ibrutinib and/or rituximab themselves or to the excipients in their formulation). 14. Positive test results for chronic HBV infection (defined as positive HBsAg serology). 15. Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing and taking specific antiviral prophylaxis, according to local policy. Patients who have protective titers of hepatitis B surface antibody (HBsAb) after vaccination are eligible. 16. Positive test results for hepatitis C. Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA. 17. HIV infection or immunodeficiency. 18. Active, severe infections 19. Pregnancy or breastfeeding. 20. Clinically significant cardiovascular diseases such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the New York Heart Association Functional Classification. 21. Any serious medical or psychiatric illness likely to interfere with participation in this clinical study. 22. Prior history of malignancies other than MZL within 3 years,with the exception of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer. 23. Current enrolment or participation in another therapeutic clinical trial within 28 days prior to treatment start

Study Design


Intervention

Drug:
Ibrutinib
capsules for oral intake in a dosage of 560 mg (four capsules) daily
Rituximab
Concentrate solution for infusion - intravenous use; Solution for injection - subcutaneous use.

Locations

Country Name City State
Belgium CHU UCL Namur / site Godinne Yvoir
France Institut Bergonié Bordeaux
France IHBN - CHU Côte de Nacre Caen
France CHU d'Estaing Clermont-Ferrand Cedex 1
France CHU Dijon Bourgogne - Hôpital François Mitterand Dijon
France CHU de Grenoble - Hôpital Albert MICHALLON La Tronche
France CHU de Montpellier Montpellier Cedex 05
France Saint Louis Hospital Paris
France Centre Hospitalier Lyon Sud PIERRE-BENITE Cedex
France CHU de Rennes Pontchaillou Rennes Cedex 9
France CHRU de Strasbourg Strasbourg
France IUCT Oncopole Toulouse Toulouse
France CHU de Tours - Hôpital Bretonneau Tours Cedex 01
France CHU de Nancy - Hôpital Brabois Vandœuvre-lès-Nancy
Italy Azienda Ospedaliera Universitaria Ospedali Riuniti - Università Politecnica delle Marche Ancona
Italy IRCCS Centro di Riferimento Oncologico di Aviano Aviano PN
Italy Giovanni Paolo II/I.R.C.C.S. Istituto Tumori Bari
Italy A.O. Spedali Civili di Brescia Brescia
Italy Ospedale Oncologico Businco Cagliari
Italy AAST Grande Ospedale Metropolitano Niguarda Milano
Italy Fondazione IRCCS - Cà Granda - Ospedale Maggiore Policlinico Milano
Italy Fondazione IRCCS - Istituto Nazionale dei Tumori Milano
Italy Ospedale San Raffaele Milano MI
Italy Fondazione IRCCS - Policlinico San Matteo Pavia
Italy Ospedale degli Infermi Ponderano BI
Italy U.O. Ematologia AUSL Ravenna Ravenna
Italy Azienda Ospedaliera Arcispedale Santa Maria Nuova IRCCS Reggio Emilia
Italy Università degli Studi di Roma La Sapienza Roma
Italy A.O.U. Città della Salute e della Scienza di Torino Ospedale Molinette Torino TO
Italy Azienda Sanitaria Universitaria Giuliano Isontina (ASUGI) Trieste
Italy Ospedale di Circolo e Fondazione Macchi di Varese Varese
Portugal Instituto Português de Oncologia de Lisboa Francisco Gentil, E.P.E. Lisboa
Switzerland Kantonalspital Baden Baden
Switzerland Istituto Oncologico della Svizzera Italiana (IOSI) Bellinzona TI
Switzerland Inselspital Bern Bern
Switzerland Hôpitaux Universitaires de Genève Genève
Switzerland Universitätsspital Zürich Zürich

Sponsors (1)

Lead Sponsor Collaborator
International Extranodal Lymphoma Study Group (IELSG)

Countries where clinical trial is conducted

Belgium,  France,  Italy,  Portugal,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Complete Response Rate at 12 months The proportion of patients with complete response after 12 months from treatment start 12 months after treatment start
Primary Progression Free Survival at 5 years The proportion of patients without disease progression after 5 years from treatment start 5 years from treatment start
Secondary Number of treatment-Emerging Adverse Events Analysis of incidence, severity and relationship of adverse events graded according to NCI Common Toxicity Criteria, version 4.0 From the time of informed consent signature until 28 days after treatment discontinuation or until resolution of all treatment-related AEs, whichever occurs later
Secondary Complete Response Rate at 24 months The proportion of patients with complete response after 24 months from treatment start 24 months from treatment start
Secondary Overall Response Rate at 12 and 24 months The proportion of responding patients (partial and complete responses) assessed at 12 and 24 months after treatment start 12 and 24 months after treatment start
Secondary Overall survival The time from the date of treatment start to the date of death from any cause From the date of treatment start to the date of death due to any cause until 5 years from treatment discontinuation
See also
  Status Clinical Trial Phase
Completed NCT02254772 - A Phase I/II Study of Intratumoral Injection of SD-101 Phase 1/Phase 2
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT01427881 - Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Phase 2
Completed NCT01701232 - Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's Lymphoma Phase 3
Completed NCT01233921 - Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer N/A
Completed NCT01093586 - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2
Completed NCT00078858 - Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Phase 1/Phase 2
Completed NCT00003196 - Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma N/A
Terminated NCT01678443 - Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies Phase 1
Active, not recruiting NCT01815749 - Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma Phase 1
Withdrawn NCT02281279 - Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Terminated NCT01408043 - Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma N/A
Withdrawn NCT01238146 - Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00608361 - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery Phase 1
Terminated NCT00288067 - Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00098891 - MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00118170 - Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function Phase 1
Completed NCT00438880 - Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00026182 - Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Phase 2
Completed NCT00004241 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Phase 1